New! Sign up for our free email newsletter.
Science News
from research organizations

Regenerative medicine offering new treatment for bronchopleural fistulas

Date:
June 24, 2016
Source:
Mayo Clinic
Summary:
For the first time in human application, researchers successfully closed an open wound on the upper chest caused by postoperative complications of lung removal. The protocol and approach were based on an ongoing trial investigating this method to treat anal fistulas in Crohn's disease.
Share:
FULL STORY

When current treatment isn't enough, patients at Mayo Clinic often are among the first to benefit from innovative therapies, new techniques and technologies. For the first time in human application, Mayo Clinic researchers successfully closed an open wound on the upper chest caused by postoperative complications of lung removal. The findings appear in the journal Stem Cells Translational Medicine.

Called bronchopleural fistulas, these wounds are holes that lead from the large airways in the lungs to the membrane that lines the lungs. Standard surgical approaches for these fistulas induce poor health and death.

"Current management is not reliably successful," says Dennis Wigle, M.D., Ph.D., Mayo Clinic thoracic surgeon and lead author of the paper. "After exhausting therapeutic options, and with declining health of the patient, we moved toward a new approach. The protocol and approach were based on an ongoing trial investigating this method to treat anal fistulas in Crohn's disease."

Stem cells were harvested from the patient's abdominal tissue and seeded onto a bioabsorbable mesh. The mesh was surgically implanted at the site of the fistula. Follow up imaging indicated that the fistula was closed and remained healed. More than a year-and-a-half later, the patient remains asymptomatic and has been able to resume activities of daily living.

The paper describes the case of a 63-year-old female patient, who was referred to Mayo Clinic for treatment of a large bronchopleural fistula. With current therapies offering little relief, researchers turned to regenerative medicine for an innovative treatment.

"To our knowledge, this case represents the first in human report of surgically placed stem cells to repair a large, multiply recurrent bronchopleural fistula. The approach was well tolerated suggesting the potential for expanded use," says Dr. Wigle.

While the procedure had success in this case, it is unclear the degree to which the treatment itself contributed to the healing of the fistula. The researchers urge further investigation on bronchopleural fistulas and the use of stem cells in their treatment.


Story Source:

Materials provided by Mayo Clinic. Note: Content may be edited for style and length.


Journal Reference:

  1. Johnathon M. Aho, Allan B. Dietz, Darcie J. Radel, Greg W. Butler, Mathew Thomas, Timothy J. Nelson, Brian T. Carlsen, Stephen D. Cassivi, Zachary T. Resch, William A. Faubion, Dennis A. Wigle. Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells. Stem Cells Translational Medicine, June 2016 DOI: 10.5966/sctm.2016-0078

Cite This Page:

Mayo Clinic. "Regenerative medicine offering new treatment for bronchopleural fistulas." ScienceDaily. ScienceDaily, 24 June 2016. <www.sciencedaily.com/releases/2016/06/160624121624.htm>.
Mayo Clinic. (2016, June 24). Regenerative medicine offering new treatment for bronchopleural fistulas. ScienceDaily. Retrieved November 21, 2024 from www.sciencedaily.com/releases/2016/06/160624121624.htm
Mayo Clinic. "Regenerative medicine offering new treatment for bronchopleural fistulas." ScienceDaily. www.sciencedaily.com/releases/2016/06/160624121624.htm (accessed November 21, 2024).

Explore More

from ScienceDaily

RELATED STORIES